$LPCN
Lipocine Inc. Stock $lpcn

$lpcn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224009127 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$7.617M	$216.2K	-$2.851M
YoY Change	13749.41%		-670.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.576M	$1.135M	$4.905M
YoY Change	22.4%	27.44%	20.74%
% of Gross Profit
Research & Development	$2.819M	$1.675M	$10.18M
YoY Change	-9.25%	0.27%	18.91%
% of Gross Profit
Depreciation & Amortization	$8.510K	$8.000K	$29.00K
YoY Change	76.56%	211.28%	205.26%
% of Gross Profit
Operating Expenses	$4.395M	$2.810M	$15.08M
YoY Change	0.02%	9.71%	19.5%
Operating Profit	$3.223M		-$17.93M
YoY Change	-174.28%		47.95%
Interest Expense	$331.4K	$299.4K
YoY Change		0.75%
% of Operating Profit	10.28%
Other Income/Expense, Net	$291.3K	$12.27K	$1.580M
YoY Change	-37.84%	-64.16%	16.03%
Pretax Income	$3.514M	-$2.282M	-$16.35M
YoY Change	-190.8%	2.34%	51.99%
Income Tax	$200.00	$560.00	$755.00
% Of Pretax Income	0.01%
Net Earnings	$3.514M	-$2.282M	-$16.35M
YoY Change	-190.79%	2.35%	51.99%
Net Earnings / Revenue	46.13%	-1055.67%
Basic Earnings Per Share	$0.66		-$3.10
Diluted Earnings Per Share	$0.66	-$0.43	-$3.14
COMMON SHARES
Basic Shares Outstanding	5.316M shares	5.316M shares	5.270M shares
Diluted Shares Outstanding	5.358M shares		5.270M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.63M	$22.04M	$22.04M
YoY Change	-14.68%	-32.26%	-32.26%
Cash & Equivalents	$3.081M	$4.772M	$4.772M
Short-Term Investments	$21.55M	$17.26M	$17.26M
Other Short-Term Assets	$583.1K	$773.4K	$773.4K
YoY Change	-65.82%	-49.28%	-49.28%
Inventory
Prepaid Expenses
Receivables	$100.1K	$52.25K	$52.25K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$25.32M	$22.86M	$22.86M
YoY Change	-17.31%	-33.03%	-33.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$107.6K	$116.1K	$116.1K
YoY Change	-17.73%	-11.77%	-11.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$23.75K	$23.75K	$23.75K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$131.3K	$139.8K	$139.9K
YoY Change	-96.15%	-95.9%	-95.9%
TOTAL ASSETS
Total Short-Term Assets	$25.32M	$22.86M	$22.86M
Total Long-Term Assets	$131.3K	$139.8K	$139.9K
Total Assets	$25.45M	$23.00M	$23.00M
YoY Change	-25.21%	-38.73%	-38.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$671.4K	$1.396M	$1.396M
YoY Change	-15.7%	132.51%	132.51%
Accrued Expenses	$761.5K	$1.218M	$1.218M
YoY Change	-32.83%	13.06%	13.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.490M	$2.632M	$2.632M
YoY Change	-22.79%	56.82%	56.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.490M	$2.632M	$2.632M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.490M	$2.632M	$2.632M
YoY Change	-27.73%	37.93%	37.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$196.3M	-$199.8M
YoY Change	4.79%	8.91%
Common Stock	$8.860K	$8.860K
YoY Change	0.09%	0.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$40.71K	$40.71K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$23.96M	$20.37M	$20.37M
YoY Change
Total Liabilities & Shareholders Equity	$25.45M	$23.00M	$23.00M
YoY Change	-25.21%	-38.73%	-38.73%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$3.514M	-$2.282M	-$16.35M
YoY Change	-190.79%	2.35%	51.99%
Depreciation, Depletion And Amortization	$8.510K	$8.000K	$29.00K
YoY Change	76.56%	211.28%	205.26%
Cash From Operating Activities	$2.408M	-$2.022M	-$11.87M
YoY Change	-161.29%	9.97%	-0.86%
INVESTING ACTIVITIES
Capital Expenditures		$9.170K	$13.17K
YoY Change		-90.52%	-90.16%
Acquisitions
YoY Change
Other Investing Activities	-$4.090M	$2.736M	$13.10M
YoY Change	-173.57%	1.59%	-9.22%
Cash From Investing Activities	-$4.090M	$2.727M	$13.08M
YoY Change	-173.63%	5.02%	-8.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$404.6K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$8.100K	-5.300K	$404.6K
YoY Change	34.64%	-10.17%	-119.02%
NET CHANGE
Cash From Operating Activities	$2.408M	-2.022M	-$11.87M
Cash From Investing Activities	-$4.090M	2.727M	$13.08M
Cash From Financing Activities	-$8.100K	-5.300K	$404.6K
Net Change In Cash	-$1.690M	699.1K	$1.623M
YoY Change	-204.3%	-6.98%	720.06%
FREE CASH FLOW
Cash From Operating Activities	$2.408M	-$2.022M	-$11.87M
Capital Expenditures		$9.170K	$13.17K
Free Cash Flow	$2.408M	-$2.031M	-$11.88M
YoY Change	-161.23%	4.95%	-1.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001535955
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent		usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent		usd
CY2022Q4	LPCN	Warrant Liability Current Portion WarrantLiabilityCurrentPortion		usd
CY2023Q4	LPCN	Warrant Liability Non Current Portion WarrantLiabilityNonCurrentPortion		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	LPCN	Minimum Guaranteed Royalties Revenue Reversal Of Variable Consideration MinimumGuaranteedRoyaltiesRevenueReversalOfVariableConsideration		usd
CY2023	us-gaap	Interest Expense InterestExpense		usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2023	us-gaap	Accretion Expense AccretionExpense		usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2022	LPCN	Write Off Of Contract Asset Due To Variable Consideration Revenue Reversal WriteOffOfContractAssetDueToVariableConsiderationRevenueReversal		usd
CY2023	LPCN	Increase Decrease In Litigation Settlement Liability IncreaseDecreaseInLitigationSettlementLiability		usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2023	LPCN	End Of Loan Payment EndOfLoanPayment		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	LPCN	Accrued Final Payment Charge On Debt AccruedFinalPaymentChargeOnDebt		usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36357
CY2023	dei	Entity Registrant Name EntityRegistrantName	LIPOCINE INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-0370688
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 Arapeen Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 202
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84108
CY2023	dei	City Area Code CityAreaCode	801
CY2023	dei	Local Phone Number LocalPhoneNumber	994-7383
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	LPCN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	25600000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5315830	shares
CY2023	dei	Auditor Firm AuditorFirmId	270
CY2023	dei	Auditor Name AuditorName	Tanner LLC
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4771758	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3148496	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	17263788	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29381410	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	52254	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	80427	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	579428	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	773424	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	945319	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	22861224	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	34135080	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	3252500	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1182191	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1153530	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	116095	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131589	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23753	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23753	usd
CY2023Q4	us-gaap	Assets Assets	23001072	usd
CY2022Q4	us-gaap	Assets Assets	37542922	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1395977	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	600388	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1218486	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1077738	usd
CY2023Q4	LPCN	Warrant Liability Current Portion WarrantLiabilityCurrentPortion	17166	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2631629	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1678126	usd
CY2022Q4	LPCN	Warrant Liability Non Current Portion WarrantLiabilityNonCurrentPortion	229856	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2631629	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1907982	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5316166	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5235166	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5315830	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5234830	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8860	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8852	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220171250	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	219112164	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	336	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	336	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	40712	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	40712	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7259	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20321	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-199777214	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183425043	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20369443	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35634940	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23001072	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37542922	usd
CY2023	LPCN	Revenue Recognition Services Licensing Fee RevenueRecognitionServicesLicensingFee	109987	usd
CY2022	LPCN	Revenue Recognition Services Licensing Fee RevenueRecognitionServicesLicensingFee	500000	usd
CY2023	LPCN	Minimum Guaranteed Royalties Revenue Reversal Of Variable Consideration MinimumGuaranteedRoyaltiesRevenueReversalOfVariableConsideration	2960805	usd
CY2023	us-gaap	Revenues Revenues	-2850818	usd
CY2022	us-gaap	Revenues Revenues	500000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10175251	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8556888	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4904888	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4062487	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	15080139	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	12619375	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-17930957	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12119375	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1366940	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	572578	usd
CY2022	us-gaap	Interest Expense InterestExpense	27098	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	212690	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	565940	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	250000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1579630	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1361420	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16351327	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10757955	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	755	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16352082	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	89	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16352171	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10758636	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.10
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.06
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5269671	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5231681	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.15
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5269671	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5256169	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16352082	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27580	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2305	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16324502	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10760941	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	45570018	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2305	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	636140	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	211423	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	21700	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35634940	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35634940	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35634940	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16352082	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27580	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	654438	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	80	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-80	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	404567	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20369443	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20369443	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16352082	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10758636	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28661	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9453	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	654438	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	636140	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	5842	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-212690	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-565940	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	250000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	952651	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	122048	usd
CY2023	LPCN	Write Off Of Contract Asset Due To Variable Consideration Revenue Reversal WriteOffOfContractAssetDueToVariableConsiderationRevenueReversal	2960805	usd
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-28173	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-166826	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-709933	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-218072	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-333085	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-569146	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	795589	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-688954	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	140748	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	61280	usd
CY2022	LPCN	Increase Decrease In Litigation Settlement Liability IncreaseDecreaseInLitigationSettlementLiability	-1250000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11865991	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11968819	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13167	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133831	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	22902147	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	45074462	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	36000000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	59502000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13084686	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14293707	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	1666667	usd
CY2022	LPCN	End Of Loan Payment EndOfLoanPayment	650000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	404567	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-21700	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	211423	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	404567	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2126944	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1623262	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	197944	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3148496	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2950552	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4771758	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3148496	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	21256	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	225	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	200	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	27580	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2305	usd
CY2022	LPCN	Accrued Final Payment Charge On Debt AccruedFinalPaymentChargeOnDebt	5842	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	89	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zoQGQ0XdBnHl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a) </i></b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zi8nRy9VJuea">Use of Estimates</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include those related to the timing and amount of revenue recognized from licensing agreements, stock-based compensation; income tax uncertainties; the fair value of the warrant liability and the useful lives of property and equipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16352171	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	4800000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3100000	usd
CY2023	us-gaap	Revenues Revenues	-2850818	usd
CY2022	us-gaap	Revenues Revenues	500000	usd
CY2023	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50 percent
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	654000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	636000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	654438	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	636140	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M23D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M25D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0373	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0306	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9897	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9931	pure
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	455000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.19
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.50
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	21959279	usd
CY2023Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	21976445	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	32075844	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	32305700	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10758636	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5269671	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5231681	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.10
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.06
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16352171	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10758636	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	212690	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	565940	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16564861	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11324576	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5269671	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5231681	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	24488	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5269671	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5256169	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.15
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	17256529	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8574	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1315	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	17263788	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29401731	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4651	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	24972	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	29381410	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	17256529	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	17263788	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	17256529	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	17263788	usd
CY2023	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	usd
CY2022	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	usd
CY2023	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2022	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	36000000.0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	59500000	usd
CY2023	LPCN	Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairments OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairments	0	usd
CY2022	LPCN	Other Than Temporary Impairment Credit Losses Recognized In Earnings Additions No Previous Impairments OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairments	0	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6700000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5600000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1298286	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1285119	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1182191	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1153530	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	116095	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131589	usd
CY2023	us-gaap	Depreciation Depreciation	29000	usd
CY2022	us-gaap	Depreciation Depreciation	9500	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	755	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	681	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	755	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	755	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3433893	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2259272	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3619564	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2529547	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	596	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	538	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	319214	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	314186	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	434858	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	422495	usd
CY2023	LPCN	Income Tax Reconciliation Orphan Drug Tax Credits IncomeTaxReconciliationOrphanDrugTaxCredits	26245	usd
CY2022	LPCN	Income Tax Reconciliation Orphan Drug Tax Credits IncomeTaxReconciliationOrphanDrugTaxCredits	42976	usd
CY2023	LPCN	Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Liability Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount	-44665	usd
CY2022	LPCN	Effective Income Tax Rate Reconciliation Nondeductible Expense Warrant Liability Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantLiabilityAmount	-118847	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1042	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	755	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1188535	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1428167	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	35108766	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	35595940	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	45592	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	44602	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6032559	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5491805	usd
CY2023Q4	LPCN	Deferred Tax Assets Orphan Drug Tax Credit DeferredTaxAssetsOrphanDrugTaxCredit	1274204	usd
CY2022Q4	LPCN	Deferred Tax Assets Orphan Drug Tax Credit DeferredTaxAssetsOrphanDrugTaxCredit	1240982	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3945862	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1997787	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	167371	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	69273	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47762889	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45868556	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	47762889	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	45868556	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7227	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9052	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7227	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9052	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7227	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9052	usd
CY2023Q4	LPCN	Deferred Tax Assetdeferred Tax Liability DeferredTaxAssetdeferredTaxLiability	47755662	usd
CY2022Q4	LPCN	Deferred Tax Assetdeferred Tax Liability DeferredTaxAssetdeferredTaxLiability	45859504	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47755662	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45859504	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45900000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1900000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2900000	usd
CY2023	LPCN	Operating Loss Carry Forwards Limitations On Use Amount OperatingLossCarryForwardsLimitationsOnUseAmount	1100000	usd
CY2023	LPCN	Operating Loss Carry Forwards Preownership Change Amount OperatingLossCarryForwardsPreownershipChangeAmount	9800000	usd
CY2023	LPCN	Operating Loss Forgive Pre Ownership Change Amount OperatingLossForgivePreOwnershipChangeAmount	3300000	usd
CY2023	LPCN	Tax Credit Carryforward Pre Ownership Change Amount TaxCreditCarryforwardPreOwnershipChangeAmount	1200000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	138600000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	4400000	usd
CY2023	LPCN	Operating Loss Carry Forwards Expiration Date1 OperatingLossCarryForwardsExpirationDate1	Approximately $33.7 million of the NOL will expire between 2024 and 2034 and $52.4 million of the NOL will expire 2035 through 2037. Pursuant to the Tax Cuts and Jobs Act of 2017, NOL’s generated in 2018 and subsequent years have an unlimited carryforward therefore the 2023, 2022, 2020, 2019 and 2018 NOL of $52.5 million can be carried forward indefinitely. The research and development credits will begin to expire in 2033 through 2043.
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	366290	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	61346	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	427636	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	355000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	341000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	reverse stock split of 1-for-17
CY2015Q4	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	63.96
CY2023Q4	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	0.001
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	262247	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.21
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	194228	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M2D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	42.72
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	229856	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-212690	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	17166	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	102000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	94000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-009127-index-headers.html	Edgar Link	pending
0001493152-24-009127-index.html	Edgar Link	pending
0001493152-24-009127.txt	Edgar Link	pending
0001493152-24-009127-xbrl.zip	Edgar Link	pending
ex10-28.htm	Edgar Link	pending
ex10-28_001.jpg	Edgar Link	pending
ex10-28_002.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
lpcn-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
lpcn-20231231_cal.xml	Edgar Link	unprocessable
lpcn-20231231_def.xml	Edgar Link	unprocessable
lpcn-20231231_lab.xml	Edgar Link	unprocessable
lpcn-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LPCN
Lipocine Inc. Stock $lpcn

2024 Q1 Form 10-K Financial Statement

#000149315224009127 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN Lipocine Inc. Stock $lpcn

2024 Q1 Form 10-K Financial Statement

#000149315224009127 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN
Lipocine Inc. Stock $lpcn